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 Abstract 
Chylothorax is a well recognized complication after neonatal cardiothoracic surgery. 
Management strategies include cessation of enteral feedings, repeated aspiration, chest drainage, 
and total parenteral nutrition. Somatostatin and its analogue, octreotide, have been used with 
promising results. The authors present three cases of neonatal postoperative chylothorax in 
which octreotide was used. After literature review, we can say that octreotide is relatively safe, 
and may reduce clinical course and complications associated with neonatal postoperative 
chylothorax. One should be aware of possible association between octreotide and necrotizing 
enterocolitis. Prospective controlled trials supporting octreotide use are lacking. 
 Octreotide in the treatment of neonatal postoperative chylothorax: report of three cases 
and literature review. 
 
Chylothorax is a well recognized complication after neonatal cardiothoracic surgery. Diagnosis 
is established by needle aspiration or at chest tube insertion. The “milky” pleural aspirate with 
raised triglycerides and predominance of lymphocytes confirms chylothorax. Although exact 
etiology of chylothorax following surgery remains unknown, various theories have been 
proposed, including disruption of lymphatics, injury to the thoracic duct, and back pressure 
phenomenon of the visceral lymphatics leading to small breaks in the thoracic duct.
1
 
Management strategies include cessation of enteral feedings, repeated aspiration, chest drainage, 
and total parenteral nutrition. Ligation of the thoracic duct, pleurodesis of pleuroperitoneal 
shunting is reserved for refractory cases.
2
 Somatostatin and its analogue, octreotide, have been 
used in treating chylothorax after various cardiothoracic procedures with promising results. The 
authors present three cases of neonatal postoperative chylothorax in which octreotide was used. 
 
Case Reports 
Patient 1 
A 36-week gestation, 2.46-kg girl was submitted to laparotomy for right diaphragmatic hernia 
repair in day two of life. On eighth postoperative day respiratory distress developed. Chest x-ray 
showed a moderate right pleural effusion. A 10F chest tube was inserted, draining 54ml of 
chylous and another 63 ml during the following 24h. Oral feeding was discontinued, and 
parenteral nutrition started. There was initial decrease in pleural drainage, but on 14th 
postoperative day there was considerable raise in thoracic tube output and octreotide infusion 
was started. We used initial dose of 2 µg/kg/h and progressively raised it to maximum dose of 
10 µg/kg/h. Chylothorax resolved on 13th day of treatment and thoracic tube was removed 
(Figure 1.). On 33rd postoperative (day 19th of octreotide treatment), patient was extubated. 
Control chest x-ray revealed small pleural effusion that resolved in the following 48h without 
need for aspiration. Tapering for octreotide was initiated on 22nd of treatment. No side effects 
of octreotide therapy were noted. Medium chain triglyceride (MCT) feeds were introduced on 
24th day of treatment and maternal milk was initiated six days after that.  
Patient 2 
A 37-week gestation, 2.37-kg boy was submitted to laparotomy for left diaphragmatic hernia 
repair in day two of life. He also had bilateral undescended testis. On second postoperative day 
a moderate left pleural effusion was noted on chest x-ray. A 10F chest tube was inserted and 
fluid analysis revealed chylothorax. Enteral feeding had not been initiated yet. 24H drainage 
started at 60ml and rose to 218ml within three days (Figure 2.). On forth postoperative day we 
started 1 µg/kg/h octreotide infusion. Octreotide dose was progressively increased until 
maximum dose of 8 µg/kg/h, on 9th day. By that time, drainage suddenly decreased. MCT diet 
was introduced in that same day. Complete resolution of chylothorax was achieved on 12th day 
of treatment. No side effects were noted. Chest tube was removed and the patient was extubated. 
Regular milk formula was initiated thirteen days after that without pleural effusion recurrence. 
Patient 3 
A 37-week gestation, 3.02-kg boy was submitted to left thoracotomy for esophageal atresia type 
C repair on first day of life. He also had a small patent foramen ovale not requiring any 
intervention. On 11th postoperative day respiratory distress obliged reintubation. Chest x-ray 
revealed bilateral pleural effusion. 81Ml of chylous was aspirated on the right side. On 12th 
postoperative day another 14mL was aspirated and a chest tube was left in place (Figure 3.). 
Oral feeding had not been initiated yet. Octreotide was promptly initiated at a starting dose of 
0.5 µg/kg/h and progressively increased until 10 µg/kg/h. There was temporarily decrease of 
thoracic output when maximum dose was achieved, but it started increasing by the 25th day of 
treatment. On 30th day of treatment pleurodesis was performed using povidone-iodine solution. 
Chylothorax resolved within six days. Thoracic tube was removed eight days after pleurodesis. 
Octreotide was stopped on the tenth day. The patient was extubated and started on regular milk 
formula. 
 
Discussion 
Chylothorax after neonatal surgery is usually a transient disorder that will resolve after a period 
of diminished flow through the thoracic lymphatics. Diminished lymphatic flow can be 
accomplished by minimizing chyle production, through the use of MCT diet, or (as is usually 
required) by the discontinuation of enteral feedings altogether. Conservative approach usually 
entails prolonged pleural drainage, mechanical ventilation, and total parental nutrition. Reported 
complications of such management include hypoproteinemia, coagulopathy, lymphopenia, 
hypogammaglobulinemia, line sepsis, and ventilator-associated ling injury. Surgical 
intervention is recommended if chylous drainage persists after 2-5 weeks of conservative 
management. Surgical options include thoracic duct ligation, pleuroperitoneal shunting, 
pleurectomy, or pleurodesis.
3
 Pleurodesis is one way to obtain pleural adhesion, obliterating 
chylous leaks. Available agents include talc, bleomycin, tetracycline, OK-432, and povidone-
iodine.
4,5
 
The use of somatostatin to treat chylothorax was first reported in an adult in 1990
6
 and in a 
neonate in 2001
7
. Octreotide is a synthetic somatostatin analog that has been used in the 
management of persistent hyperinsulinemic states, in newborn infants
8
. Somatostatin and 
octreotide cause mild vasoconstriction of splanchnic vessels and reduces gastric, pancreatic and 
intestinal secretions as well as intestinal absorption and hepatic venous flow, which collectively 
may act in concert to reduce chyle flow.
9
 Reported side-effects include transient loose stools, 
nausea, flatulence, hypoglycemia and liver dysfunction. Two cases of necrotizing enterocolitis 
due to octreotide have been reported in neonates. The first case reported was a newborn with a 
chylothorax after gastroschisis correction.
10
 The other case was a 22-day-old boy with refractory 
hypoglycemia.
 11
  
Since the first two cases of reported use of octreotide in postoperative neonatal chylothorax,
7
 26 
other cases have been reported in the literature
1, 2, 3, 10,
 
12, 13, 14, 15, 16, 17, 18,
 
19, 20
 (Table 1). There is 
significant heterogeneity in dosing regimens, therapeutic durations, and time to star octreotide. 
All the authors used octreotide as second line treatment. Octreotide was initiated when total 
parenteral nutrition (TPN) or MCT feeds alone failed in resolving chylothorax. Days to 
octreotide therapy initiation ranged from 4 to 31. Therapy duration ranged from 3 to 49 days. 
Intravenous infusion has been the most used mode of administration, although subcutaneous and 
intravenous bolus have been used. Intravenous infusion dosing ranged from 0.3 to 10 µg/kg/h 
(7-240 µg/kg/day). Most authors began treatment with a lower dose and progressively raised it, 
but the dose to elicit significant reduction in lymphorrhea was quite variable. There was no 
apparent consensus about how long therapy should be continued after chylothorax resolution. 
Tapering of octreotide was longer if chylous effusion recurred. 
There is no consensus about enteral feeding while on octreotide therapy either. Most of patients 
were on TPN until resolution of chylothorax. Some were on MCT feeds from the beginning and 
other started them before finishing octreotide therapy. Reported side-effects included loose 
stools, transient rash, and the case of necrotizing enterocolitis reported earlier. Gonzalez et al.
1
 
reported that one of their patients died of sepsis while on octreotide therapy, but point of origin 
was not specified. 
It is difficult to evaluate octreotide therapy success rate for neonatal chylothorax, especially 
those due to surgical intervention. Although most of initial reports presented cases where 
octreotide or somatostatin had been effective, some recent series of patients presented cases 
where pleurodesis or surgical procedure was needed to cease chylous drainage. On their series 
of chylothorax post-congenital diaphragmatic hernia repair, Gonzalez et al.
1
 reported that none 
of their four patients on octreotide therapy had their thoracic tube output consistently reduced, 
despise a maximum dose of 96 µg/kg/day. Copons Férnandez et al.
14
 presented a series of 22 
neonatal chylothorax of different etiologies. In their series, five of 10 patients who did not 
respond to TPN were successfully treated with octreotide. Analyzing the postoperative 
chylothoraxes alone, there was a 50% success rate for a maximum dose of 36 µg/kg/day. 
In our experience, two of three patients had their chylothorax resolved within 12 days after 
initiation of octreotide therapy. Both these patients had a sudden decrease on chylous output 
when maximum dose was achieved. The case requiring pleurodesis had a bilateral effusion and 
large amount of chylous drainage. Massive chylous leakage has been appointed as one of the 
reasons for octreotide failure in older children.
21
  
Because there was some concern regarding chylothorax recurrence, octreotide therapy was 
maintained and even tapered upwards for some days. In either case, we cannot be sure what was 
the exact role of octreotide on chylothorax resolution or was it due to TPN and bowel rest alone. 
 
Conclusion 
Despite the significant heterogeneity of case reports published, one can say that octreotide is 
relatively safe, and may reduce clinical course and complications associated with neonatal 
postoperative chylothorax. The association between octreotide and necrotizing enterocolitis 
should be noted. Prospective controlled trials comparing various octreotide regimens and 
conventional therapy are needed. 
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Figure 1 – Drainage of chylothorax (blue line) and octreotide (rose line) dosage in patient 1. 
 
 
Figure 2 – Drainage of chylothorax (blue line) and octreotide dosage (rose line) in patient 2. 
 
 Figure 3 - Drainage of chylothorax (blue line) and octreotide dosage (rose line) in patient 3. 
Arrow represents povidone-iodine pleurodesis. 
Reference n Surgical condition 
Chylothorax 
commenced 
POD 
Treatment 
commenced 
POD 
Duration of 
treatment 
(days) 
Maximum 
dose 
(µg/kg/day) 
Treatment effect Complications 
Moreira-
Pinto et al. 
2010 3 
CDH 
CDH 
EA 
8 
2 
11 
14 
4 
11 
24 
20 
40 
240 
192 
240 
Resolution on 
11th day 
Resolution on 
12th day 
Failed. 
None 
Hung et al. 
2009
12
 
1 CDH 
First few 
days 
8 5 24 
Resolution on 
2nd day 
None 
Gonzalez 
et al. 
2009
1
 6 CDH Unclear Unclear Unclear 96 
Did not 
consistently 
reduce tube 
output in any of 
the patients 
One died of 
sepsis while on 
octreotide 
Prada 
Arias et al. 
2008
13
 
1 AE 7 16 49 240 
Resolution on 
49th day 
None 
Copons 
Fernández 
et al. 
2008
14
 
8 
CDH 
CHD 
CHD 
CHD 
CHD 
CHD 
CHD 
CHD 
6 
7 
5 
5 
8 
7 
2 
6 
One week 
after 
treatment 
with NPT 
alone. 
Unclear.* 
36 
12 
36 
12 
36 
36 
36 
36 
Resolved 
Resolved 
Failed** 
Resolved 
Resolved 
Failed** 
Failed** 
Failed** 
None 
Rocha et 
al. 2007
15
 
1 EA 3 15 13 164 
Reslution on 11th 
day 
None 
Chan et al 
2005
16
 
1 CHD*** Unclear 20 8 Unclear Failed Unclear 
González 
Santacruz 
et al 
2005
17
  
2 
CDH 
CDH 
Unclear Unclear 
8 
10 
84 
144 
Resolution on 8th 
day 
Resolution on 
10th day 
None 
Clarke et 
al. 2005
19
 
1 EA 15 27 14 84 Prompt resolution None 
Mohseni-
Bod et al. 
2004
10
 
1 
Iatrogenic cardiac 
perforation/aortic 
coarctation 
14 16 3 96 Prompt resolution 
Onset of NEC 
while on 
octreotide 
Tibballs et 
al. 2004
18
 
1 
CHD 
lymphangiectasia 
4 8 4 120 Prompt resolution None 
Goyal et 
al. 2003
2
 
1 CDH 7 16 9 10 
Resolution on 
2nd day 
None 
Table
Au et al. 
2003
3
 
1 Gastroschisis 1 33 7 84 
Resolution on 5th 
day 
None 
Pettitt et 
al. 2002
20
 
1 CHD 1 34 3 51 
Resolution on 3rd 
day 
Transient 
cutaneous rash 
Buettiker 
et al. 
2001
7
 
2 
CHD 
CHD 
3 
1 
17 
32 
14 
15 
240 
240 
Resolution on 
12th day 
Resolution on 
11th day 
None 
Loose stools 
Table 1 – Neonatal postoperative chylothorax treated with ocreotide/somatostatin reported in the literature. 
CDH = congenital diaphragmatic hernia; CHD = congenital heart disease; EA = esophageal atresia; i.v. intravenous; TAPVC = total anomalous pulmonary venous 
connection, POD = posoperative day; s.c. subcutaneous 
* Treatment was suspended when maximum dose was achieved without clear response. For those responding, treatment was maintained during 8-12 days at minimal 
effective dose. 
** Surgical treatment was indicated when chylothorax persisted for more than four weeks after diagnosis. 
*** Failed ductal ligation on 15th POD. 
